GSE87211

Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Source
GEO
Assay
microarray
Organism
Homo sapiens
Whole-study samples
363 samples
Specimen
Tissue
Reported/interpreted study design
Disease/model vs control Design classification does not establish patient pairs.
Comparison type
Tumor vs normal
Contributors
Hu Y
Contact name
Yue Hu
Submission date
2016-09-22
Last update
2018-01-09
Organization
NCI
Department
Genetic
Public date
2017-11-28
Experiment types
Expression profiling by array
Platforms
GPL13497 Agilent-026652 Whole Human Genome Microarray 4x44K v2 (Probe Name version)
Series type
Series
SubSeries
Not available
BioProject
PRJNA343887

Summary

To understand the molecular mechanism of rectal cancer and develop markers for disease prognostication, we generated and explored a dataset from 243 rectal cancer patients by gene expression microarray analysis of cancer samples and matched controls, and SNP-arrays of germline DNA. We found that two of the loci most strongly linked with colorectal cancer (CRC) risk, 8q24 (upstream of MYC) and 18q21 (in the intron of SMAD7), as well as 20q13 (in the intron of LAMA5), are tightly associated with the prognosis of rectal cancer patients. For SNPs on 18q21 (rs12953717 and rs4464148) and 20q13 (rs4925386), alleles that correlate with higher risk for the development of CRC are associated with shorter disease free survival (DFS). However, for rs6983267 on 8q24, the low risk allele is associated with a higher risk for recurrence and metastasis after surgery, and importantly, is strongly correlated with the resistance of CRC cell lines to chemoradiotherapy (CRT). We also found that although MYC expression is dramatically increased in cancer, patients with higher levels of MYC have a better prognosis. The expression of SMAD7 is weakly correlated with DFS. Notably, the presence of the 8q24 and 18q21 SNP alleles is not correlated with expression levels of MYC and SMAD7. rs4464148, and probably rs6983267 and rs4925386, are linked with overall survival time of patients. In conclusion, we show that several CRC risk SNPs detect subpopulations of rectal cancer patients with poor prognosis, and that rs6983267 probably affects prognosis through interfering with the resistance of cancer cells to CRT.

Overall design

Dataset of expression microarray of cancer samples and matched mucosa control, as well as SNP arrays of DNA extracted from peripheral blood lymphocytes from 230 rectal cancer patients was generated and analyzed together with patient's clinical data and long-term follow-up.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
363 GSM samples
 Primary source
recount3

Planned trusted source for processed count availability.

 No match found
Expression Atlas

Planned source for curated expression experiment links.

 No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

21 linked publications 21 DOIs

Primary publication

  1. Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery. Genes, chromosomes & cancer, 2018

Related publications

  1. KAT2A alleviates the glucose starvation-induced mitochondrial oxidative stress and ferroptosis to promote colon cancer progression. Apoptosis : an international journal on programmed cell death, 2025
  2. DNA methylation driven genes shape prognosis and tumor immune landscape in rectal cancer. Discover oncology, 2026
  3. NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer genetics, 2020
  4. Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictors. EBioMedicine, 2024
  5. Construction and validation of golgi apparatus-related genes as predictors of the immune microenvironment and prognosis in colorectal cancer. Translational oncology, 2026
  6. Identification of a novel macrophage-related prognostic signature in colorectal cancer. Scientific reports, 2024
  7. A pseudouridine-related prognostic model of colorectal cancer based on single-cell sequencing analysis and transcriptome analysis. Scientific reports, 2026
  8. Integrative Multiomics and Single-Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer. Human mutation, 2026
  9. Construction and validation of a novel Ferroptosis-related gene signature predictive model in rectal Cancer. BMC genomics, 2022
  10. Identification of a mitophagy-related gene signature for predicting overall survival and response to immunotherapy in rectal cancer. BMC cancer, 2025
  11. BATF promotes tumor progression and association with FDG PET-derived parameters in colorectal cancer. Journal of translational medicine, 2024
  12. Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma. Cancer biomarkers : section A of Disease markers, 2023
  13. Prognostic Implication of the m(6)A RNA Methylation Regulators in Rectal Cancer. Frontiers in genetics, 2021
  14. Identification of anoikis-related genes to develop a risk model and predict the prognosis and tumor microenvironment in rectal adenocarcinoma. Frontiers in genetics, 2025
  15. Molecular Characteristics, Oncogenic Roles, and Relevant Immune and Pharmacogenomic Features of EVA1B in Colorectal Cancer. Frontiers in immunology, 2022
  16. Machine learning identifies PYGM as a macrophage polarization-linked metabolic biomarker in rectal cancer prognosis. Frontiers in immunology, 2025
  17. Intratumor heterogeneity score reveals immune landscape and survival stratification in colorectal cancer. Frontiers in immunology, 2025
  18. Gene Expression-Based Colorectal Cancer Prediction Using Machine Learning and SHAP Analysis. Genes, 2026
  19. Development of a 5-mRNAsi-related gene signature to predict the prognosis of colon adenocarcinoma. PeerJ, 2023
  20. Prognostic implications of metabolism-associated gene signatures in colorectal cancer. PeerJ, 2020
Available

Metadata Quality Components

Persisted metadata quality

100 pts
Clarity
100%
Weight
100 pts

Sample source clarity: All samples have source metadata and clear GSE/GSM accessions. Group clarity: Rule-based grouping found both case and control samples. Disease clarity: Disease or condition metadata normalized. Tissue clarity: Anatomical source metadata normalized. Treatment clarity: No unclear treatment split detected in the sample metadata. Replicate clarity: No pooled sample or technical replicate flags detected. Data availability clarity: Dataset-level processed or raw data availability is explicit.

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Colorectal cancer, colorectal neoplasm Disease context came from Normalization rules.
  • Likely case group Tumor sample 203 samples
  • Likely control group Control 160 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded assay: microarray cohorts are separated from the RNA-seq intent. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Tissue. Comparison suitability: 0%.
  • Interpreted disease metadata: Colorectal cancer, Colorectal neoplasm.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 21 publications; 21 DOIs available: PMID 29119627, PMID 32871287, PMID 32953273, PMID 34149792, PMID 35250982.
  • Publication context: Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery.. Genes, chromosomes & cancer, 2018. PMID 29119627. DOI 10.1002/gcc.22512.
  • Publication context: NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.. Cancer genetics, 2020. PMID 32871287. DOI 10.1016/j.cancergen.2020.08.006.
  • Publication context: Prognostic implications of metabolism-associated gene signatures in colorectal cancer.. PeerJ, 2020. PMID 32953273. DOI 10.7717/peerj.9847.
  • Publication context: 18 additional linked PubMed publications are available.

Cautions

  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

showing 500 of 2269 fields

Sample Group Preview

showing 100 of 363 preview rows Show Hide
Study totals: Case 203 | Control 160 | Unassigned 0 | Excluded 0 | Ambiguous 0 showing 100 of 363 preview rows
Group Role Accession Title Source / characteristics Reason
Tumor sample Case GSM2325238 Patient 1 tumor sample Rectal tumor Patient: Tum Patient 1; Age: 55.6; Gender: F; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -4.08; Death due to tumor: 0; Survival time (month): 41.92 Explicit sample label case marker detected.
Tumor sample Case GSM2325239 Patient 2 tumor sample Rectal tumor Patient: Tum Patient 2; Age: 65.6; Gender: M; Tissue: Rectal tumor; Kras mutation: I21L; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 40.27; Death due to tumor: 0; Survival time (month): 40.27 Explicit sample label case marker detected.
Tumor sample Case GSM2325240 Patient 3 tumor sample Rectal tumor Patient: Tum Patient 3; Age: 62.7; Gender: M; Tissue: Rectal tumor; Kras mutation: G12D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 29.62; Death due to tumor: 0; Survival time (month): 29.62 Explicit sample label case marker detected.
Tumor sample Case GSM2325241 Patient 4 tumor sample Rectal tumor Patient: Tum Patient 4; Age: 61.8; Gender: M; Tissue: Rectal tumor; Kras mutation: G12A; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 32.65; Death due to tumor: 0; Survival time (month): 32.65 Explicit sample label case marker detected.
Tumor sample Case GSM2325242 Patient 5 tumor sample Rectal tumor Patient: Tum Patient 5; Age: 52.1; Gender: F; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 31.59; Death due to tumor: 0; Survival time (month): 31.59 Explicit sample label case marker detected.
Tumor sample Case GSM2325243 Patient 6 tumor sample Rectal tumor Patient: Tum Patient 6; Age: 59.1; Gender: M; Tissue: Rectal tumor; Kras mutation: G12C; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 34.52; Death due to tumor: 0; Survival time (month): 34.52 Explicit sample label case marker detected.
Tumor sample Case GSM2325244 Patient 7 tumor sample Rectal tumor Patient: Tum Patient 7; Age: 70.7; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 32.68; Death due to tumor: 0; Survival time (month): 32.68 Explicit sample label case marker detected.
Tumor sample Case GSM2325245 Patient 8 tumor sample Rectal tumor Patient: Tum Patient 8; Age: 60.7; Gender: M; Tissue: Rectal tumor; Kras mutation: G12D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 30.31; Death due to tumor: 0; Survival time (month): 30.31 Explicit sample label case marker detected.
Tumor sample Case GSM2325246 Patient 9 tumor sample Rectal tumor Patient: Tum Patient 9; Age: 55; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 28.08; Death due to tumor: 0; Survival time (month): 28.08 Explicit sample label case marker detected.
Tumor sample Case GSM2325247 Patient 10 tumor sample Rectal tumor Patient: Tum Patient 10; Age: 53.1; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 27.55; Death due to tumor: 0; Survival time (month): 27.55 Explicit sample label case marker detected.
Tumor sample Case GSM2325248 Patient 11 tumor sample Rectal tumor Patient: Tum Patient 11; Age: NA; Gender: M; Tissue: Rectal tumor; Kras mutation: A146T; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: NA; Lymph node metastasis after rct: NA; Metastasis after rct: NA; Cancer recurrance after surgery: 0; Disease free time (month): NA; Death due to tumor: 0; Survival time (month): NA Explicit sample label case marker detected.
Tumor sample Case GSM2325249 Patient 12 tumor sample Rectal tumor Patient: Tum Patient 12; Age: 58.6; Gender: M; Tissue: Rectal tumor; Kras mutation: G12C; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 14.93; Death due to tumor: 0; Survival time (month): 14.93 Explicit sample label case marker detected.
Tumor sample Case GSM2325250 Patient 13 tumor sample Rectal tumor Patient: Tum Patient 13; Age: 68.5; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 23.38; Death due to tumor: 0; Survival time (month): 23.38 Explicit sample label case marker detected.
Tumor sample Case GSM2325251 Patient 14 tumor sample Rectal tumor Patient: Tum Patient 14; Age: 58.8; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 2; Lymph node metastasis before rct: 1; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): 6.71; Death due to tumor: 0; Survival time (month): 25.81 Explicit sample label case marker detected.
Tumor sample Case GSM2325252 Patient 15 tumor sample Rectal tumor Patient: Tum Patient 15; Age: 70.1; Gender: M; Tissue: Rectal tumor; Kras mutation: G12S; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: NA; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 13.02; Death due to tumor: 0; Survival time (month): 13.02 Explicit sample label case marker detected.
Tumor sample Case GSM2325253 Patient 16 tumor sample Rectal tumor Patient: Tum Patient 16; Age: 77.6; Gender: F; Tissue: Rectal tumor; Kras mutation: G12D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: NA; Metastasis before rct: NA; Depth of invasion after rct: 4; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 34.72; Death due to tumor: 0; Survival time (month): 34.72 Explicit sample label case marker detected.
Tumor sample Case GSM2325254 Patient 17 tumor sample Rectal tumor Patient: Tum Patient 17; Age: 68.5; Gender: F; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: NA; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 2; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -2.63; Death due to tumor: 0; Survival time (month): 18.28 Explicit sample label case marker detected.
Tumor sample Case GSM2325255 Patient 18 tumor sample Rectal tumor Patient: Tum Patient 18; Age: 75.2; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: NA; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 2; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -3.32; Death due to tumor: 1; Survival time (month): 10.26 Explicit sample label case marker detected.
Tumor sample Case GSM2325256 Patient 19 tumor sample Rectal tumor Patient: Tum Patient 19; Age: 76.3; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: NA; Metastasis before rct: NA; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 10.62; Death due to tumor: 0; Survival time (month): 10.62 Explicit sample label case marker detected.
Tumor sample Case GSM2325257 Patient 20 tumor sample Rectal tumor Patient: Tum Patient 20; Age: 38.2; Gender: M; Tissue: Rectal tumor; Kras mutation: G13D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 8.25; Death due to tumor: 0; Survival time (month): 8.25 Explicit sample label case marker detected.
Tumor sample Case GSM2325258 Patient 21 tumor sample Rectal tumor Patient: Tum Patient 21; Age: 61.1; Gender: F; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 2; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -0.62; Death due to tumor: 1; Survival time (month): 5.75 Explicit sample label case marker detected.
Tumor sample Case GSM2325259 Patient 22 tumor sample Rectal tumor Patient: Tum Patient 22; Age: 69.4; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 23.28; Death due to tumor: 0; Survival time (month): 23.28 Explicit sample label case marker detected.
Tumor sample Case GSM2325260 Patient 23 tumor sample Rectal tumor Patient: Tum Patient 23; Age: 54.2; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 23.8; Death due to tumor: 0; Survival time (month): 23.8 Explicit sample label case marker detected.
Tumor sample Case GSM2325261 Patient 24 tumor sample Rectal tumor Patient: Tum Patient 24; Age: 57.4; Gender: F; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 1; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 7.33; Death due to tumor: 0; Survival time (month): 7.33 Explicit sample label case marker detected.
Tumor sample Case GSM2325262 Patient 25 tumor sample Rectal tumor Patient: Tum Patient 25; Age: 61.3; Gender: M; Tissue: Rectal tumor; Kras mutation: Q61P; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 1; Disease free time (month): 15.25; Death due to tumor: 0; Survival time (month): 24.1 Explicit sample label case marker detected.
Tumor sample Case GSM2325263 Patient 26 tumor sample Rectal tumor Patient: Tum Patient 26; Age: 47; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 22.55; Death due to tumor: 0; Survival time (month): 22.55 Explicit sample label case marker detected.
Tumor sample Case GSM2325264 Patient 27 tumor sample Rectal tumor Patient: Tum Patient 27; Age: 62.7; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 22.22; Death due to tumor: 0; Survival time (month): 22.22 Explicit sample label case marker detected.
Tumor sample Case GSM2325265 Patient 28 tumor sample Rectal tumor Patient: Tum Patient 28; Age: 51.3; Gender: M; Tissue: Rectal tumor; Kras mutation: G13D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 17.98; Death due to tumor: 0; Survival time (month): 17.98 Explicit sample label case marker detected.
Tumor sample Case GSM2325266 Patient 29 tumor sample Rectal tumor Patient: Tum Patient 29; Age: 73.3; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 1; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): 0; Death due to tumor: 0; Survival time (month): 6.25 Explicit sample label case marker detected.
Tumor sample Case GSM2325267 Patient 30 tumor sample Rectal tumor Patient: Tum Patient 30; Age: 47.2; Gender: F; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -2.99; Death due to tumor: 0; Survival time (month): 13.12 Explicit sample label case marker detected.
Tumor sample Case GSM2325268 Patient 31 tumor sample Rectal tumor Patient: Tum Patient 31; Age: 72.7; Gender: F; Tissue: Rectal tumor; Kras mutation: G12S; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 16.21; Death due to tumor: 0; Survival time (month): 16.21 Explicit sample label case marker detected.
Tumor sample Case GSM2325269 Patient 32 tumor sample Rectal tumor Patient: Tum Patient 32; Age: 38.8; Gender: M; Tissue: Rectal tumor; Kras mutation: G12C; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 4; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 2; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 6.38; Death due to tumor: 0; Survival time (month): 6.38 Explicit sample label case marker detected.
Tumor sample Case GSM2325270 Patient 33 tumor sample Rectal tumor Patient: Tum Patient 33; Age: 75.5; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 13.02; Death due to tumor: 0; Survival time (month): 13.02 Explicit sample label case marker detected.
Tumor sample Case GSM2325271 Patient 34 tumor sample Rectal tumor Patient: Tum Patient 34; Age: 80; Gender: F; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 2.96; Death due to tumor: 0; Survival time (month): 2.96 Explicit sample label case marker detected.
Tumor sample Case GSM2325272 Patient 35 tumor sample Rectal tumor Patient: Tum Patient 35; Age: 60.9; Gender: M; Tissue: Rectal tumor; Kras mutation: G12D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 13.05; Death due to tumor: 0; Survival time (month): 13.05 Explicit sample label case marker detected.
Tumor sample Case GSM2325273 Patient 36 tumor sample Rectal tumor Patient: Tum Patient 36; Age: 76.3; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 1.74; Death due to tumor: 0; Survival time (month): 1.74 Explicit sample label case marker detected.
Tumor sample Case GSM2325274 Patient 37 tumor sample Rectal tumor Patient: Tum Patient 37; Age: 49.5; Gender: F; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 1; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 12.59; Death due to tumor: 0; Survival time (month): 12.59 Explicit sample label case marker detected.
Tumor sample Case GSM2325275 Patient 38 tumor sample Rectal tumor Patient: Tum Patient 38; Age: 49.9; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 11.57; Death due to tumor: 0; Survival time (month): 11.57 Explicit sample label case marker detected.
Tumor sample Case GSM2325276 Patient 39 tumor sample Rectal tumor Patient: Tum Patient 39; Age: 57.6; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 9.83; Death due to tumor: 0; Survival time (month): 9.83 Explicit sample label case marker detected.
Tumor sample Case GSM2325277 Patient 40 tumor sample Rectal tumor Patient: Tum Patient 40; Age: 77.3; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 8.28; Death due to tumor: 0; Survival time (month): 8.28 Explicit sample label case marker detected.
Tumor sample Case GSM2325278 Patient 41 tumor sample Rectal tumor Patient: Tum Patient 41; Age: 72.4; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 1; Disease free time (month): 22.68; Death due to tumor: 0; Survival time (month): 22.68 Explicit sample label case marker detected.
Tumor sample Case GSM2325279 Patient 42 tumor sample Rectal tumor Patient: Tum Patient 42; Age: 76.3; Gender: M; Tissue: Rectal tumor; Kras mutation: G13D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 20.19; Death due to tumor: 0; Survival time (month): 20.19 Explicit sample label case marker detected.
Tumor sample Case GSM2325280 Patient 43 tumor sample Rectal tumor Patient: Tum Patient 43; Age: 61.4; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 0; Death due to tumor: 0; Survival time (month): 0 Explicit sample label case marker detected.
Tumor sample Case GSM2325281 Patient 44 tumor sample Rectal tumor Patient: Tum Patient 44; Age: 66.3; Gender: F; Tissue: Rectal tumor; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 0; Death due to tumor: 0; Survival time (month): 0 Explicit sample label case marker detected.
Tumor sample Case GSM2325282 Patient 45 tumor sample Rectal tumor Patient: Tum Patient 45; Age: 65.6; Gender: M; Tissue: Rectal tumor; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 0; Death due to tumor: 0; Survival time (month): 0 Explicit sample label case marker detected.
Tumor sample Case GSM2325283 Patient 46 tumor sample Rectal tumor Patient: Tum Patient 46; Age: 68.4; Gender: M; Tissue: Rectal tumor; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: NA; Disease free time (month): NA; Death due to tumor: NA; Survival time (month): NA Explicit sample label case marker detected.
Tumor sample Case GSM2325284 Patient 47 tumor sample Rectal tumor Patient: Tum Patient 47; Age: 78.9; Gender: M; Tissue: Rectal tumor; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 2; Lymph node metastasis before rct: 0; Metastasis before rct: NA; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: NA; Disease free time (month): NA; Death due to tumor: NA; Survival time (month): NA Explicit sample label case marker detected.
Tumor sample Case GSM2325285 Patient 48 tumor sample Rectal tumor Patient: Tum Patient 48; Age: 65.8; Gender: M; Tissue: Rectal tumor; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: NA; Disease free time (month): NA; Death due to tumor: NA; Survival time (month): NA Explicit sample label case marker detected.
Tumor sample Case GSM2325286 Patient 49 tumor sample Rectal tumor Patient: Tum Patient 49; Age: 57.1; Gender: F; Tissue: Rectal tumor; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: NA; Disease free time (month): NA; Death due to tumor: NA; Survival time (month): NA Explicit sample label case marker detected.
Tumor sample Case GSM2325287 Patient 50 tumor sample Rectal tumor Patient: Tum Patient 50; Age: 74.1; Gender: M; Tissue: Rectal tumor; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 1; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 1; Disease free time (month): 29.03; Death due to tumor: 0; Survival time (month): 29.03 Explicit sample label case marker detected.
153 additional case samples are hidden from this preview.
Control Control GSM2325441 Patient 1 mucosa control sample Mucosa Patient: Con Patient 1; Age: 55.6; Gender: F; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -4.08; Death due to tumor: 0; Survival time (month): 41.92 Sample-local control marker detected.
Control Control GSM2325442 Patient 2 mucosa control sample Mucosa Patient: Con Patient 2; Age: 65.6; Gender: M; Tissue: Mucosa; Kras mutation: I21L; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 40.27; Death due to tumor: 0; Survival time (month): 40.27 Sample-local control marker detected.
Control Control GSM2325443 Patient 3 mucosa control sample Mucosa Patient: Con Patient 3; Age: 62.7; Gender: M; Tissue: Mucosa; Kras mutation: G12D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 29.62; Death due to tumor: 0; Survival time (month): 29.62 Sample-local control marker detected.
Control Control GSM2325444 Patient 4 mucosa control sample Mucosa Patient: Con Patient 4; Age: 61.8; Gender: M; Tissue: Mucosa; Kras mutation: G12A; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 32.65; Death due to tumor: 0; Survival time (month): 32.65 Sample-local control marker detected.
Control Control GSM2325445 Patient 5 mucosa control sample Mucosa Patient: Con Patient 5; Age: 52.1; Gender: F; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 31.59; Death due to tumor: 0; Survival time (month): 31.59 Sample-local control marker detected.
Control Control GSM2325446 Patient 6 mucosa control sample Mucosa Patient: Con Patient 6; Age: 59.1; Gender: M; Tissue: Mucosa; Kras mutation: G12C; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 34.52; Death due to tumor: 0; Survival time (month): 34.52 Sample-local control marker detected.
Control Control GSM2325447 Patient 7 mucosa control sample Mucosa Patient: Con Patient 7; Age: 70.7; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 32.68; Death due to tumor: 0; Survival time (month): 32.68 Sample-local control marker detected.
Control Control GSM2325448 Patient 8 mucosa control sample Mucosa Patient: Con Patient 8; Age: 60.7; Gender: M; Tissue: Mucosa; Kras mutation: G12D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 30.31; Death due to tumor: 0; Survival time (month): 30.31 Sample-local control marker detected.
Control Control GSM2325449 Patient 9 mucosa control sample Mucosa Patient: Con Patient 9; Age: 55; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 28.08; Death due to tumor: 0; Survival time (month): 28.08 Sample-local control marker detected.
Control Control GSM2325450 Patient 10 mucosa control sample Mucosa Patient: Con Patient 10; Age: 53.1; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 27.55; Death due to tumor: 0; Survival time (month): 27.55 Sample-local control marker detected.
Control Control GSM2325451 Patient 11 mucosa control sample Mucosa Patient: Con Patient 11; Age: NA; Gender: M; Tissue: Mucosa; Kras mutation: A146T; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: NA; Lymph node metastasis after rct: NA; Metastasis after rct: NA; Cancer recurrance after surgery: 0; Disease free time (month): NA; Death due to tumor: 0; Survival time (month): NA Sample-local control marker detected.
Control Control GSM2325452 Patient 12 mucosa control sample Mucosa Patient: Con Patient 12; Age: 58.6; Gender: M; Tissue: Mucosa; Kras mutation: G12C; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 14.93; Death due to tumor: 0; Survival time (month): 14.93 Sample-local control marker detected.
Control Control GSM2325453 Patient 13 mucosa control sample Mucosa Patient: Con Patient 13; Age: 68.5; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 23.38; Death due to tumor: 0; Survival time (month): 23.38 Sample-local control marker detected.
Control Control GSM2325454 Patient 14 mucosa control sample Mucosa Patient: Con Patient 14; Age: 58.8; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 2; Lymph node metastasis before rct: 1; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): 6.71; Death due to tumor: 0; Survival time (month): 25.81 Sample-local control marker detected.
Control Control GSM2325455 Patient 15 mucosa control sample Mucosa Patient: Con Patient 15; Age: 70.1; Gender: M; Tissue: Mucosa; Kras mutation: G12S; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: NA; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 13.02; Death due to tumor: 0; Survival time (month): 13.02 Sample-local control marker detected.
Control Control GSM2325456 Patient 16 mucosa control sample Mucosa Patient: Con Patient 16; Age: 77.6; Gender: F; Tissue: Mucosa; Kras mutation: G12D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: NA; Metastasis before rct: NA; Depth of invasion after rct: 4; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 34.72; Death due to tumor: 0; Survival time (month): 34.72 Sample-local control marker detected.
Control Control GSM2325457 Patient 17 mucosa control sample Mucosa Patient: Con Patient 17; Age: 68.5; Gender: F; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: NA; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 2; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -2.63; Death due to tumor: 0; Survival time (month): 18.28 Sample-local control marker detected.
Control Control GSM2325458 Patient 18 mucosa control sample Mucosa Patient: Con Patient 18; Age: 75.2; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: NA; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 2; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -3.32; Death due to tumor: 1; Survival time (month): 10.26 Sample-local control marker detected.
Control Control GSM2325459 Patient 19 mucosa control sample Mucosa Patient: Con Patient 19; Age: 76.3; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: NA; Metastasis before rct: NA; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 10.62; Death due to tumor: 0; Survival time (month): 10.62 Sample-local control marker detected.
Control Control GSM2325460 Patient 20 mucosa control sample Mucosa Patient: Con Patient 20; Age: 38.2; Gender: M; Tissue: Mucosa; Kras mutation: G13D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 8.25; Death due to tumor: 0; Survival time (month): 8.25 Sample-local control marker detected.
Control Control GSM2325461 Patient 21 mucosa control sample Mucosa Patient: Con Patient 21; Age: 61.1; Gender: F; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 2; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -0.62; Death due to tumor: 1; Survival time (month): 5.75 Sample-local control marker detected.
Control Control GSM2325462 Patient 22 mucosa control sample Mucosa Patient: Con Patient 22; Age: 69.4; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 23.28; Death due to tumor: 0; Survival time (month): 23.28 Sample-local control marker detected.
Control Control GSM2325463 Patient 23 mucosa control sample Mucosa Patient: Con Patient 23; Age: 54.2; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 23.8; Death due to tumor: 0; Survival time (month): 23.8 Sample-local control marker detected.
Control Control GSM2325464 Patient 24 mucosa control sample Mucosa Patient: Con Patient 24; Age: 57.4; Gender: F; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 1; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 7.33; Death due to tumor: 0; Survival time (month): 7.33 Sample-local control marker detected.
Control Control GSM2325465 Patient 25 mucosa control sample Mucosa Patient: Con Patient 25; Age: 61.3; Gender: M; Tissue: Mucosa; Kras mutation: Q61P; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 1; Disease free time (month): 15.25; Death due to tumor: 0; Survival time (month): 24.1 Sample-local control marker detected.
Control Control GSM2325466 Patient 26 mucosa control sample Mucosa Patient: Con Patient 26; Age: 47; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 22.55; Death due to tumor: 0; Survival time (month): 22.55 Sample-local control marker detected.
Control Control GSM2325467 Patient 27 mucosa control sample Mucosa Patient: Con Patient 27; Age: 62.7; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 22.22; Death due to tumor: 0; Survival time (month): 22.22 Sample-local control marker detected.
Control Control GSM2325468 Patient 28 mucosa control sample Mucosa Patient: Con Patient 28; Age: 51.3; Gender: M; Tissue: Mucosa; Kras mutation: G13D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 17.98; Death due to tumor: 0; Survival time (month): 17.98 Sample-local control marker detected.
Control Control GSM2325469 Patient 29 mucosa control sample Mucosa Patient: Con Patient 29; Age: 73.3; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 1; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): 0; Death due to tumor: 0; Survival time (month): 6.25 Sample-local control marker detected.
Control Control GSM2325470 Patient 30 mucosa control sample Mucosa Patient: Con Patient 30; Age: 47.2; Gender: F; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 1; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 1; Cancer recurrance after surgery: 1; Disease free time (month): -2.99; Death due to tumor: 0; Survival time (month): 13.12 Sample-local control marker detected.
Control Control GSM2325471 Patient 31 mucosa control sample Mucosa Patient: Con Patient 31; Age: 72.7; Gender: F; Tissue: Mucosa; Kras mutation: G12S; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 16.21; Death due to tumor: 0; Survival time (month): 16.21 Sample-local control marker detected.
Control Control GSM2325472 Patient 32 mucosa control sample Mucosa Patient: Con Patient 32; Age: 38.8; Gender: M; Tissue: Mucosa; Kras mutation: G12C; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 4; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 2; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 6.38; Death due to tumor: 0; Survival time (month): 6.38 Sample-local control marker detected.
Control Control GSM2325473 Patient 33 mucosa control sample Mucosa Patient: Con Patient 33; Age: 75.5; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 13.02; Death due to tumor: 0; Survival time (month): 13.02 Sample-local control marker detected.
Control Control GSM2325474 Patient 34 mucosa control sample Mucosa Patient: Con Patient 34; Age: 80; Gender: F; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 2.96; Death due to tumor: 0; Survival time (month): 2.96 Sample-local control marker detected.
Control Control GSM2325475 Patient 35 mucosa control sample Mucosa Patient: Con Patient 35; Age: 60.9; Gender: M; Tissue: Mucosa; Kras mutation: G12D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 13.05; Death due to tumor: 0; Survival time (month): 13.05 Sample-local control marker detected.
Control Control GSM2325476 Patient 36 mucosa control sample Mucosa Patient: Con Patient 36; Age: 76.3; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 1.74; Death due to tumor: 0; Survival time (month): 1.74 Sample-local control marker detected.
Control Control GSM2325477 Patient 37 mucosa control sample Mucosa Patient: Con Patient 37; Age: 49.5; Gender: F; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 1; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 12.59; Death due to tumor: 0; Survival time (month): 12.59 Sample-local control marker detected.
Control Control GSM2325478 Patient 38 mucosa control sample Mucosa Patient: Con Patient 38; Age: 49.9; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 11.57; Death due to tumor: 0; Survival time (month): 11.57 Sample-local control marker detected.
Control Control GSM2325479 Patient 39 mucosa control sample Mucosa Patient: Con Patient 39; Age: 57.6; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 9.83; Death due to tumor: 0; Survival time (month): 9.83 Sample-local control marker detected.
Control Control GSM2325480 Patient 40 mucosa control sample Mucosa Patient: Con Patient 40; Age: 77.3; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 8.28; Death due to tumor: 0; Survival time (month): 8.28 Sample-local control marker detected.
Control Control GSM2325481 Patient 41 mucosa control sample Mucosa Patient: Con Patient 41; Age: 72.4; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 1; Disease free time (month): 22.68; Death due to tumor: 0; Survival time (month): 22.68 Sample-local control marker detected.
Control Control GSM2325482 Patient 42 mucosa control sample Mucosa Patient: Con Patient 42; Age: 76.3; Gender: M; Tissue: Mucosa; Kras mutation: G13D; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 20.19; Death due to tumor: 0; Survival time (month): 20.19 Sample-local control marker detected.
Control Control GSM2325483 Patient 43 mucosa control sample Mucosa Patient: Con Patient 43; Age: 61.4; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 0; Death due to tumor: 0; Survival time (month): 0 Sample-local control marker detected.
Control Control GSM2325484 Patient 44 mucosa control sample Mucosa Patient: Con Patient 44; Age: 66.3; Gender: F; Tissue: Mucosa; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 0; Death due to tumor: 0; Survival time (month): 0 Sample-local control marker detected.
Control Control GSM2325485 Patient 45 mucosa control sample Mucosa Patient: Con Patient 45; Age: 65.6; Gender: M; Tissue: Mucosa; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 0; Disease free time (month): 0; Death due to tumor: 0; Survival time (month): 0 Sample-local control marker detected.
Control Control GSM2325486 Patient 46 mucosa control sample Mucosa Patient: Con Patient 46; Age: 68.4; Gender: M; Tissue: Mucosa; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 3; Lymph node metastasis after rct: 1; Metastasis after rct: 0; Cancer recurrance after surgery: NA; Disease free time (month): NA; Death due to tumor: NA; Survival time (month): NA Sample-local control marker detected.
Control Control GSM2325487 Patient 47 mucosa control sample Mucosa Patient: Con Patient 47; Age: 78.9; Gender: M; Tissue: Mucosa; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 2; Lymph node metastasis before rct: 0; Metastasis before rct: NA; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: NA; Disease free time (month): NA; Death due to tumor: NA; Survival time (month): NA Sample-local control marker detected.
Control Control GSM2325488 Patient 48 mucosa control sample Mucosa Patient: Con Patient 48; Age: 65.8; Gender: M; Tissue: Mucosa; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 2; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: NA; Disease free time (month): NA; Death due to tumor: NA; Survival time (month): NA Sample-local control marker detected.
Control Control GSM2325489 Patient 49 mucosa control sample Mucosa Patient: Con Patient 49; Age: 57.1; Gender: F; Tissue: Mucosa; Kras mutation: NA; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 1; Metastasis before rct: 0; Depth of invasion after rct: 0; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: NA; Disease free time (month): NA; Death due to tumor: NA; Survival time (month): NA Sample-local control marker detected.
Control Control GSM2325490 Patient 50 mucosa control sample Mucosa Patient: Con Patient 50; Age: 74.1; Gender: M; Tissue: Mucosa; Kras mutation: WT; Preoperative radiochemotherapy (rct): 5-FU + RT; Depth of invasion before rct: 3; Lymph node metastasis before rct: 0; Metastasis before rct: 0; Depth of invasion after rct: 1; Lymph node metastasis after rct: 0; Metastasis after rct: 0; Cancer recurrance after surgery: 1; Disease free time (month): 29.03; Death due to tumor: 0; Survival time (month): 29.03 Sample-local control marker detected.
110 additional control samples are hidden from this preview.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.